Tamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404
Crossref DOI link: https://doi.org/10.1007/s00280-014-2545-2
Published Online: 2014-07-24
Published Print: 2014-09
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Shien, Tadahiko
Iwata, Hiroji
Fukutomi, Takashi
Inoue, Kenichi
Aogi, Kenjiro
Kinoshita, Takayuki
Ando, Jiro
Takashima, Seiki
Nakamura, Kenichi
Shibata, Taro
Fukuda, Haruhiko
License valid from 2014-07-24